The COVID-19 pandemic has illuminated an ongoing concern about antimicrobial resistance in dermatology and requires a recommitment from clinicians to follow guidelines that promote good stewardship.
The use of prophylactic oral antibiotic in the day prior to elective colon surgery is associated with a reduced incidence of surgical-site infections.
Research results underscore the importance of understanding the characteristics of Legionnaires’ disease and the need for early diagnosis.
Antibiotic prescription rates are high in low- and middle-income countries, with a pooled prevalence proportion of antibiotic prescribing of 52%.
The FDA has granted 510(k) clearance to binx io (binx health) for women’s health, a molecular point-of-care diagnostic testing platform for detecting chlamydia and gonorrhea in approximately 30 minutes.
Preliminary evidence suggests some benefit with statins.
The FDA has granted Breakthrough Device designation to ResistancePlus GC (SpeeDx), a test that detects ciprofloxacin susceptibility and provides resistance information to aid in the treatment of gonorrhea.
Heritage Pharmaceuticals has initiated a voluntary recall of Amikacin Sulfate Injection, USP, 1g/4mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL) after microbial growth was detected in 1 unreleased sublot of both products.